Biogen Reports 52-Week Lupus Skin Drug Data, Shows Durable Results
Biogen's litifilimab showed sustained skin disease improvement at 52 weeks in a Phase 2 CLE trial, with placebo switchers responding within four weeks.
Biogen Inc. on Thursday released the longest dataset yet for its experimental drug litifilimab in cutaneous lupus erythematosus, showing continued clinical improvements in skin disease activity through 52 weeks in the ongoing AMETHYST Phase 2/3 study.
The results were presented at the European Academy of Dermatology and Venereology 2026 Congress in Vienna, Austria. Participants who remained on litifilimab throughout the double-blind, placebo-controlled period maintained improvements in skin disease activity, reinforcing the drug's potential as a first-in-class treatment for a condition that has limited therapeutic options.
Read more Corgi Insurance Launches Specialized Data Center Coverage Program →
A notable finding involved patients who crossed over from placebo to litifilimab at the 24-week mark. Those participants began experiencing a measurable treatment effect as early as four weeks after switching, suggesting a rapid onset of action that could be clinically meaningful for patients and physicians weighing treatment timelines.
Cutaneous lupus erythematosus is a chronic autoimmune skin disease that can cause scarring, disfigurement, and significant quality-of-life impairment. The AMETHYST study's Part A data, drawn from the Phase 2 portion, now represents the most extensive clinical evidence available for litifilimab in this indication, according to Biogen.
Biogen, based in Cambridge, Massachusetts, trades on the Nasdaq under the ticker BIIB. The company has positioned litifilimab as a potential first-in-class therapy targeting CLE, a disease area where regulatory approvals remain scarce. Continue reading at GlobeNewswire - Industry News on Financial Services.
